By Josh Beckerman
Shares of Inovio Pharmaceuticals fell to a 52-week low after the company reported the pricing of a $30 million offering.
The stock tumbled 40% to $2.27 in Friday trading, after falling to as low as $2.14 per share. For the year, the shares are down 63%.
Inovio said it sold 10 million shares and 10 million warrants at a combined public offering price of $3 per share and warrant. It disclosed plans for the sale on Thursday.
The company intends to use proceeds for purposes including development of its clinical pipeline, and preparing for the potential commercial launch of lead drug candidate INO-3107, if it's approved.
INO-3107, a potential treatment for recurrent respiratory papillomatosis, received Breakthrough Therapy designation from the Food and Drug Administration in September 2023.
Write to Josh Beckerman at josh.beckerman@wsj.com
(END) Dow Jones Newswires
December 13, 2024 13:11 ET (18:11 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。